Therefore, TYMS overexpression in an Ink4a/Arf null background increases the incidence of histiocytic sarcoma and can increase tumor infiltration of both histiocytic sarcomas and lymphomas compared to Ink4a/Arf−/− control (Tables 1 and 2). The gene discussed is CDKN2A; the disease is histiocytic sarcoma.